Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites.

Three volunteers were immunized by repeated exposure to the bites of Plasmodium falciparum-infected, X-irradiated mosquitoes to characterize immunologic responses and duration of protective immunity. A primary series of immunizations had been shown previously to induce sterile immunity in these volunteers against sporozoite-induced P. falciparum malaria. In the current study, antibodies to sporozoites circulated at high levels for at least 9-12 months after the volunteers were administered booster bites from X-irradiated infective mosquitoes. One volunteer challenged a second time with P. falciparum 9 months after his last immunization was again shown to be protected, whereas all 5 control subjects developed patent infections. These results set a new standard for persistence of sterile immunity against experimental P. falciparum infection.

[1]  E. Nardin,et al.  Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. , 1984, Journal of immunology.

[2]  M. Levine,et al.  Plasmodium falciparum: in vitro characterization and human infectivity of a cloned line. , 1992, Experimental parasitology.

[3]  J. Vanderberg,et al.  Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.

[4]  J. F. Young,et al.  Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. , 1987, Experimental parasitology.

[5]  V. Nussenzweig,et al.  γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites , 1987, Nature.

[6]  S. Hoffman,et al.  SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE , 1987, The Lancet.

[7]  D. Herrington,et al.  Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. , 1991, The American journal of tropical medicine and hygiene.

[8]  Myron M. Levine,et al.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites , 1987, Nature.

[9]  K. Sell,et al.  Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. , 1979, Bulletin of the World Health Organization.

[10]  K. Rieckmann,et al.  Human immunization with attenuated sporozoites. , 1990, Bulletin of the World Health Organization.

[11]  A. Moreno,et al.  Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. , 1991, International immunology.

[12]  D. Clyde,et al.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. , 1975, The American journal of tropical medicine and hygiene.

[13]  S. Hoffman,et al.  Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. , 1990, The American journal of tropical medicine and hygiene.

[14]  J. Beier,et al.  Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A , 1992, Infection and immunity.

[15]  R. Miller,et al.  Specificity of protection of man immunized against sporozoite‐induced falciparum malaria , 1973, The American journal of the medical sciences.